Mauro is the founder of Abilita Bio, Inc. and inventor of the EMP™ technology it was formed around. He has gained significant experience over 18 years of leading and contributing to membrane protein programs, especially with GPCRs, performing protein chemistry, protein engineering, crystallography and structure based drug design. Mauro has authored eighteen peer-reviewed scientific articles, including publications in Cell, Nature, PNAS, and JACS. He received his Ph.D. from the Max Planck Institute under Nobel laureate Prof. Hartmut Michel and carried out his postdoctoral studies as a Pfizer fellow in the Stevens lab at the Scripps Institute (TSRI), widely regarded as the world’s top lab for GPCR structural studies. Mauro also worked as a Scientist at Receptos, Inc. and has consulted for Eli Lilly & Company.
Chris brings more than ten years of innovation in membrane protein engineering, structural biology and drug discovery to Abilita Bio. He most recently served as a Research Scientist at Receptos, Inc. from 2009 to 2015, where he was a founding member of the scientific team and the lead inventor of critical GPCR protein engineering technologies that were patented and licensed to domestic and international industry partners. Prior to joining Receptos, Dr. Roth conducted postdoctoral research in GPCR structural biology in the laboratory of Dr. Raymond Stevens at The Scripps Research Institute (TSRI), where he also earned his PhD. Dr. Roth earned his B.S. in Molecular and Cellular Biology from the University of California at Santa Barbara.
Among his many contributions to the field of G protein-coupled receptor (GPCR) drug discovery, Alexander’s most pivotal was the personal conception and development of a generic membrane protein stability assay known as the CPM assay, widely regarded by many in the field to be transformational for the measurement of thermostability. Prior to Abilita Bio, he served in Scientific positions of increasing responsibilities at Takeda San Diego and Heptares Therapeutics, and completed his postdoctoral studies in Ray Stevens’ lab at the Scripps Institute (TSRI), and David Bredt’s lab at University of California, San Francisco. Alexander received his PhD in Biophysics from the University of California, Berkeley.
Dr. Karen Chiang brings over 10 years of molecular and cell biology experience to the team and has a broad background in the fields of plant biology, HIV and neurodegenerative diseases. Karen completed her postdoctoral training in Dr. Edward H. Koo’s laboratory at UCSD, after earning her Ph.D. in Translational Biology and Molecular Medicine from Baylor College of Medicine in Houston, Texas.
Dr. Le Li recently joined Abilita Bio as a Research Scientist and brings key expertise in membrane protein biophysical characterization, purification and formulation. Previously, she worked as an Analytical Scientist at Catalent Pharma Solutions. Dr. Li completed her postdoctoral studies at Oak Ridge National Lab after earning a Ph.D. in Chemistry from North Carolina State University.
Kin Moy, BSc